Project Grant R44GM165220

The National Institute of General Medical Sciences awarded Partillion Bioscience Corp $979,071 on September 1, 2026, under the Biomedical Research and Research Training program (CFDA 93.859) to develop nanovial kits for large-scale cell-cell interaction sequencing.

Partillion will expand compatibility of nanovials—engineered hydrogel microcontainers that compartmentalize single-cell and cell-pair interactions—across widely used off-the-shelf single-cell sequencing chemistries to broaden user access and reduce costs. The work includes developing and validating nanovial workflows with capped formats to localize interactions, integrating library preparation, and establishing quantitative success criteria for low cross-talk and robust transcript capture. Partillion will execute two large-scale use cases to demonstrate generality and value: antibody discovery using hybridoma or B-cell-antigen pairs, and innate immunity studies using NK-tumor pairs. All work will be benchmarked against standard methods, and the recipient will deliver standard operating procedures, ready-to-use kits, and curated datasets with metadata for reuse, enabling broader participation in therapeutic discovery while preserving functional fidelity.

Performance occurs in Pasadena, California. The award period runs through August 31, 2028.